Macrophage activation syndrome in the era of biologic therapy.
about
IL-1 Inhibition in Systemic Juvenile Idiopathic ArthritisClinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review.Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?Induction of Live Cell Phagocytosis by a Specific Combination of Inflammatory Stimuli.New frontiers in the treatment of systemic juvenile idiopathic arthritis.[Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases : Experiences from a German registry (GRAID2)].A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis.Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition.Interleukin-18: Biological properties and role in disease pathogenesis.H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome.Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).Anaplasma phagocytophilum-Related Defects in CD8, NKT, and NK Lymphocyte Cytotoxicity.Macrophage activation syndrome associated with griscelli syndrome type 2: case report and review of literature.Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome
P2860
Q28078134-B75F02D9-81FC-4C79-B02D-CDF00D74FE01Q36369924-0B2B413A-838C-4152-91CC-6FDB5922BA74Q38637780-57E00850-E7FC-4BCD-9EF1-59E0D4E9BE58Q38667499-653D4B67-5A49-42E0-B5DE-8FA3433E63E8Q39424746-461E4BFE-DE7F-4AF2-8519-32F336707474Q40053587-068CBE6F-0A38-400C-984A-32BC1FCFB7F4Q43615149-FFDC127D-37CE-4735-B671-7EBD62B43D33Q47150341-CAB32BC4-BCFB-415F-B371-6A2293BD5CFBQ47285927-F1A7A6D2-BD91-4124-A8B0-DFCD2F2FA56BQ47727637-3A2A65AA-0908-403F-BE70-2752F05B7BE9Q51705351-B8C1B12F-A599-4C67-8C85-FEC995E06594Q52330721-30938F0D-A95F-4B77-AABB-6B331105D486Q55288424-CB4FA9DC-4A73-46B6-A41F-2E0B0831DCBAQ55406173-42AC4FB0-DBF7-4E06-9046-30CEFC637B36Q57492392-CFBFB14B-9AF5-423A-A22F-F9C2584AC213
P2860
Macrophage activation syndrome in the era of biologic therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Macrophage activation syndrome in the era of biologic therapy.
@en
type
label
Macrophage activation syndrome in the era of biologic therapy.
@en
prefLabel
Macrophage activation syndrome in the era of biologic therapy.
@en
P2860
P356
P1476
Macrophage activation syndrome in the era of biologic therapy
@en
P2093
Alexei A Grom
P2860
P2888
P304
P356
10.1038/NRRHEUM.2015.179
P407
P577
2016-03-24T00:00:00Z
P5875
P6179
1013836098